ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies
ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to…
ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to…
Circassia has positive Phase III results from its respiratory pipeline, great news for the company…
Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials…
After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to…
Although 2016 has brought plenty of good news in medical advances, biotech is an industry…
Abivax, Celyad, Circassia and Genticel - these are all European Biotechs that took a hit…
Circassia's pipeline takes a major step back as its therapy for cat allergy gets disappointing…
Circassia is beginning a Phase III trial for its short-course immunotherapy for grass allergies. This…
Cash is floating into Biotech like never before, in the US as well as in…
There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom…